Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoNteSSa / NeoCon-F neoadjuvant chemotherapy and fertility-sparing surgery in stage IB2 cervical cancer
2023-507230-24-00Phase 2Authorised
- Sponsor
- University Health Network, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Start
- Sep 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, paclitaxel and carboplatin in Cervical Cancer (CC), sponsored by University Health Network, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting. Primary endpoint: Functional uterus rate. Planned start Sep 2023; status: authorised.
02
Drugs
cisplatinpaclitaxelcarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2023-507230-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507230-24-00.